KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Receivables (2016 - 2026)

Pacira BioSciences has reported Change in Receivables over the past 17 years, most recently at $1.6 million for Q1 2026.

  • For Q1 2026, Change in Receivables rose 118.31% year-over-year to $1.6 million; the TTM value through Mar 2026 reached $20.9 million, up 571.86%, while the annual FY2025 figure was $10.7 million, 38.64% up from the prior year.
  • Change in Receivables for Q1 2026 was $1.6 million at Pacira BioSciences, down from $8.8 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $12.7 million in Q4 2024 and troughed at -$8.6 million in Q1 2025.
  • A 5-year average of $1.7 million and a median of $1.6 million in 2026 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: plummeted 812.34% in 2022 and later soared 688.68% in 2023.
  • Year by year, Change in Receivables stood at $4.9 million in 2022, then soared by 74.56% to $8.6 million in 2023, then surged by 47.12% to $12.7 million in 2024, then tumbled by 30.45% to $8.8 million in 2025, then plummeted by 82.19% to $1.6 million in 2026.
  • Business Quant data shows Change in Receivables for PCRX at $1.6 million in Q1 2026, $8.8 million in Q4 2025, and $897000.0 in Q3 2025.